

**August 5, 2026**

To

**BSE Limited,**

Listing Department, P J Towers,  
Dalal Street,  
Mumbai – 400 001.

**National Stock Exchange of India Limited,**

Listing Department, "Exchange Plaza",  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Scrip Code: 540679**

**Trading Symbol: HALEOSLABS**

**SUB: OUTCOME OF THE 98<sup>TH</sup> BOARD MEETING.**

**Ref: Regulation 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e. **August 5, 2026**, have inter alia considered and approved the following:

- i. **Unaudited Standalone and Consolidated Financial Results** for the quarter ended June 30, 2026, as reviewed and recommended by the Audit Committee and approved by the Board of Directors.

In this regard, we are enclosing herewith a copy of un-audited (Standalone and Consolidated) financial results for the quarter ended June 30, 2026 along with the Limited Review Reports received from the Statutory Auditors of the Company on the said results.

- ii. **Re-appointment of the following Independent Directors** for a second term of 5 (five) years with effect from November 13, 2026, subject to approval of the shareholders.

| Sl. No. | Name of Director              | DIN      |
|---------|-------------------------------|----------|
| 1)      | Dr. (Mr.) Mannam Malakondaiah | 01431923 |
| 2)      | Dr. (Mr.) Srinivas Samavedam  | 02488555 |

Please note that a detailed report pursuant to sub-para 7 of para "A" of part "A" of Schedule-III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, will be submitted separately, within the prescribed timeline.




- iii. **Revision of Managerial Remuneration payable to Mr. TVVSN Murthy, (DIN: 00465198) Managing Director of the Company**, subject to approval of the Shareholders.
- iv. **Board's Report for the year ended March 31, 2026.**
- v. **Holding the 20<sup>th</sup> Annual General Meeting on Wednesday, September 30, 2026**, through Video Conferencing ('VC')/Other Audio Visual Means ('OAVM') in accordance with General Circular No. 03/2025 dated September 22, 2025 read with General Circular No. 09/2024 dated September 19, 2024 and other applicable MCA Circulars.

The above information is also available on the website of the Company at [www.haleoslabs.com](http://www.haleoslabs.com)

The meeting of the Board commenced at 12.30 pm and concluded at 01.45 pm.

**For Haleos Labs Limited**

(Formerly known as "SMS Lifesciences India Limited")

  
**Trupti Ranjan Mohanty**

Company Secretary

ICSI Memb. No. F13407



**HALEOS LABS LIMITED**

(Formerly known as SMS Lifesciences India Limited)

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Standalone Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2026**

(Rs. In Lakhs)

| S.No | Particulars                                                                                | Quarter Ended   |                 |                 | Year Ended       |
|------|--------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|------------------|
|      |                                                                                            | 30.06.2026      | 31.03.2026      | 30.06.2025      | 31.03.2026       |
|      |                                                                                            | (Unaudited)     | (Audited)       | (Unaudited)     | (Audited)        |
| 1    | Revenue From Operations                                                                    | 6,782.97        | 6,338.42        | 7,904.27        | 30,098.96        |
| 2    | Other Income                                                                               | 45.61           | 96.92           | 100.94          | 142.11           |
| 3    | <b>Total Revenue</b>                                                                       | <b>6,828.58</b> | <b>6,435.34</b> | <b>8,005.21</b> | <b>30,241.07</b> |
| 4    | <b>Expenses</b>                                                                            |                 |                 |                 |                  |
|      | (a) Cost of Materials Consumed                                                             | 3,728.42        | 3,302.37        | 3,299.94        | 14,557.49        |
|      | (b) Changes in Inventories                                                                 | (783.22)        | (733.80)        | 540.14          | (650.99)         |
|      | (c) Manufacturing Expenses                                                                 | 1,190.00        | 1,214.04        | 1,403.78        | 5,571.54         |
|      | (d) Employee Benefits Expense                                                              | 1,324.63        | 1,206.08        | 1,249.50        | 4,939.27         |
|      | (e) Finance Cost                                                                           | 181.33          | 133.68          | 173.27          | 603.42           |
|      | (f) Depreciation and Amortization Expense                                                  | 301.25          | 265.55          | 263.45          | 1,066.40         |
|      | (g) Other Expenses                                                                         | 358.58          | 729.66          | 327.33          | 1,634.83         |
|      | <b>Total Expenses - (a to g)</b>                                                           | <b>6,300.99</b> | <b>6,117.58</b> | <b>7,257.41</b> | <b>27,721.96</b> |
| 5    | <b>Profit Before Tax (3-4)</b>                                                             | <b>527.59</b>   | <b>317.76</b>   | <b>747.80</b>   | <b>2,519.11</b>  |
| 6    | <b>Tax Expenses</b>                                                                        |                 |                 |                 |                  |
|      | (1) (i) Current Tax                                                                        | 160.00          | (75.00)         | 225.00          | 550.00           |
|      | (ii) Relating to Earlier Year                                                              | -               | (17.82)         | -               | (17.82)          |
|      | (2) Deferred Tax                                                                           | 43.81           | 187.12          | 7.03            | 209.25           |
|      | <b>Total Tax Expenses</b>                                                                  | <b>203.81</b>   | <b>94.30</b>    | <b>232.03</b>   | <b>741.43</b>    |
| 7    | <b>Net Profit / (Loss) for the Period / Year (5-6)</b>                                     | <b>323.78</b>   | <b>223.46</b>   | <b>515.77</b>   | <b>1,777.68</b>  |
| 8    | <b>Other Comprehensive Income for the Period / Year (OCI):</b>                             |                 |                 |                 |                  |
|      | Items that will not be reclassified to profit or Loss:                                     |                 |                 |                 |                  |
|      | Remeasurement of post-employment benefit obligations                                       | 2.75            | 7.35            | 1.17            | 11.03            |
|      | Income Tax effect on the above                                                             | 0.80            | 2.14            | 0.34            | 3.21             |
|      |                                                                                            | 1.95            | 5.21            | 0.83            | 7.81             |
| 9    | <b>Total Comprehensive Income for the period / Year (7+8)</b>                              | <b>325.74</b>   | <b>228.67</b>   | <b>516.60</b>   | <b>1,785.49</b>  |
| 10   | Earnings Per Equity Share of Rs.10/- each<br>Basic / Diluted (not annualised)              | 10.71           | 7.39            | 17.06           | 58.80            |
| 11   | Paid-up equity share capital (Face Value of Rs.10/- each)                                  | 302.33          | 302.33          | 302.33          | 302.33           |
| 12   | Reserves excluding Revaluation Reserve<br>as per balance sheet of previous accounting year |                 |                 |                 | 21,155.36        |

**For Haleos Labs Limited**
**TVSN Murthy**  
**Managing Director**  
**DIN: 00465198**

**Notes:**

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 05th August, 2026 and have been approved by the Board of Directors at its meeting held on 05th August, 2026. The statutory auditors of the Company have carried out limited review of Standalone financial results for the quarter ended 30th June, 2026 and expressed unmodified opinion thereon.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The figures for quarter ended 31st March, 2026 are balancing figures between audited figures of the full financial year ended 31st March, 2026 and the published year to date figures upto third quarter ended 31st December, 2025, which were subjected to limited review by the auditors.
- 4 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 05-08-2026

**For Haleds Labs Limited**

**TVVSN Murthy**  
**Managing Director**  
**DIN: 00465198**





**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

**Review Report to  
The Board of Directors  
HALEOS LABS LIMITED (Formerly known as SMS Lifesciences India Limited)**

We have reviewed the accompanying statement of unaudited standalone financial results of **HALEOS LABS LIMITED (Formerly known as SMS Lifesciences India Limited)** ("the Company"), for the quarter ended 30<sup>th</sup> June 2026 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review of the interim financial information consists of making inquiries primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 05.08.2026

For Rambabu & Co.,  
Chartered Accountants  
Reg. No.002976S

  
GVL Prasad  
Partner

M.No. 026548



UDIN: 26026548PGNVJE5555

**HALEOS LABS LIMITED**  
(Formerly known as SMS Lifesciences India Limited)  
(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096  
Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Consolidated Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2026**

(Rs. In Lakhs)

| S.No | Particulars                                                                                    | Quarter Ended   |                 |                 | Year Ended       |
|------|------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|------------------|
|      |                                                                                                | 30.06.2026      | 31.03.2026      | 30.06.2025      | 31.03.2026       |
|      |                                                                                                | (Unaudited)     | (Audited)       | (Unaudited)     | (Audited)        |
| 1    | Revenue From Operations                                                                        | 7,294.23        | 7,513.91        | 8,250.46        | 33,379.45        |
| 2    | Other Income                                                                                   | 46.33           | 201.49          | 99.59           | 243.34           |
| 3    | <b>Total Revenue</b>                                                                           | <b>7,340.56</b> | <b>7,715.40</b> | <b>8,350.05</b> | <b>33,622.79</b> |
| 4    | <b>Expenses</b>                                                                                |                 |                 |                 |                  |
|      | (a) Cost of Materials Consumed                                                                 | 4,013.81        | 3,585.99        | 2,773.22        | 14,669.42        |
|      | (b) Changes in Inventories                                                                     | (1,368.21)      | (497.77)        | 672.57          | (818.45)         |
|      | (c) Manufacturing Expenses                                                                     | 1,566.05        | 1,508.02        | 1,650.46        | 6,642.58         |
|      | (d) Employee Benefits Expense                                                                  | 1,754.92        | 1,616.59        | 1,629.17        | 6,538.25         |
|      | (e) Finance Cost                                                                               | 189.96          | 142.04          | 186.52          | 644.52           |
|      | (f) Depreciation and Amortization Expense                                                      | 424.45          | 384.88          | 382.38          | 1,546.88         |
|      | (g) Other Expenses                                                                             | 415.61          | 885.09          | 353.67          | 1,879.95         |
|      | <b>Total Expenses - (a to g)</b>                                                               | <b>6,996.59</b> | <b>7,624.84</b> | <b>7,647.99</b> | <b>31,103.15</b> |
| 5    | <b>Profit Before Tax (3-4)</b>                                                                 | <b>343.97</b>   | <b>90.56</b>    | <b>702.06</b>   | <b>2,519.64</b>  |
| 6    | <b>Tax Expenses</b>                                                                            |                 |                 |                 |                  |
|      | (1) (i) Current Tax                                                                            | 160.00          | (86.00)         | 240.00          | 570.00           |
|      | (ii) Relating to Earlier Year                                                                  | -               | (17.81)         | -               | (17.81)          |
|      | (2) Mat Credit Entitlement                                                                     | -               | 11.00           | (15.00)         | (20.00)          |
|      | (3) Deferred Tax                                                                               | (0.06)          | 148.97          | 38.85           | 207.42           |
|      |                                                                                                | <b>159.94</b>   | <b>56.16</b>    | <b>263.85</b>   | <b>739.61</b>    |
| 7    | <b>Net Profit / (Loss) for the Period / Year (5-6)</b>                                         | <b>184.03</b>   | <b>34.40</b>    | <b>438.21</b>   | <b>1,780.03</b>  |
| 8    | <b>Other Comprehensive Income/(Loss) (OCI):</b>                                                |                 |                 |                 |                  |
|      | Items that will not be reclassified to statement of Profit & Loss                              |                 |                 |                 |                  |
|      | Remeasurement of post-employment benefit obligations                                           | 5.90            | 6.39            | 4.91            | 15.52            |
|      | Income Tax effect on the above                                                                 | (1.62)          | (1.89)          | (1.31)          | (4.38)           |
|      |                                                                                                | <b>4.28</b>     | <b>4.50</b>     | <b>3.60</b>     | <b>11.14</b>     |
| 9    | <b>Total comprehensive Income for the period/year (7+8)</b>                                    | <b>188.31</b>   | <b>38.90</b>    | <b>441.81</b>   | <b>1,791.17</b>  |
| 10   | <b>Profit for the year attributable to:</b>                                                    |                 |                 |                 |                  |
|      | Equity holders of the parent                                                                   | 264.66          | 43.56           | 415.69          | 1,731.20         |
|      | Non-controlling interest                                                                       | (80.63)         | (9.17)          | 22.52           | 48.83            |
| 11   | <b>Total comprehensive income for the year attributable to:</b>                                |                 |                 |                 |                  |
|      | Equity holders of the parent                                                                   | 268.01          | 48.35           | 418.18          | 1,738.95         |
|      | Non-controlling interest                                                                       | (79.70)         | (9.45)          | 23.63           | 52.22            |
| 12   | <b>Earning Per Equity Share of Rs.10/- each</b>                                                |                 |                 |                 |                  |
|      | Basic / Diluted (not annualised)                                                               | <b>8.75</b>     | <b>1.44</b>     | <b>13.75</b>    | <b>57.26</b>     |
| 13   | <b>Paid-up equity share capital (Face Value of Rs.10/- each)</b>                               | <b>302.33</b>   | <b>302.33</b>   | <b>302.33</b>   | <b>302.33</b>    |
| 14   | <b>Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year</b> |                 |                 |                 | <b>21,052.45</b> |

**For Haleos Labs Limited**

**TVVSN Murthy**  
Managing Director  
DIN: 00465198



**Notes:**

- 1 The above Consolidated Financial Results have been reviewed and recommended by the Audit Committee on 05th August, 2026 and have been approved by the Board of Directors at its meeting held on 05th August, 2026. The statutory auditors of the Company have carried out limited review of Consolidated financial results for the quarter ended 30th June, 2026 and expressed unmodified opinion thereon.
- 2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 3 The figures for quarter ended 31st March, 2026 are balancing figures between audited figures of the full financial year ended 31st March, 2026 and the published year to date figures upto third quarter ended 31st December, 2025, which were subjected to limited review by the statutory auditors
- 4 The Consolidated financial results are prepared by applying Ind AS-110 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary.
- 5 The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 6 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 05-08-2026

**For Haleos Labs Limited**

TVVSN Murthy  
Managing Director  
DIN: 00465198





**Independent Auditor's Review Report on review of Interim Consolidated Financial Results**

To the Board of Directors of  
**HALEOS LABS LIMITED (Formerly known as SMS Lifesciences India Limited)**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **HALEOS LABS LIMITED (Formerly known as SMS Lifesciences India Limited)** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> June, 2026 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by The Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities

- a. **HALEOS LABS LIMITED (Formerly known as SMS Lifesciences India Limited)**
- b. M/s. Mahi Drugs Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs. 1,025.24 lakhs, total net loss after tax of Rs.201.58 lakhs and total comprehensive income/(Loss) of Rs.(199.25) lakhs for the Quarter ended 30 June, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad

Date: 05.08.2026

For Rambabu & Co.,

Chartered Accountants

Reg. No.002976S

  
GVL Prasad

Partner

M. No. 026548



UDIN: 26026548LLOSJA1225